GHRP-6 Research Guide: Growth Hormone Releasing Peptide, Ghrelin Biology, and Anabolic Research

By Sam Smith

GHRP-6 was the compound that proved the ghrelin receptor existed before ghrelin was discovered. Cyril Bowers synthesized it in the late 1980s while systematically mapping which small peptides could stimulate pituitary GH release, and the hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) he identified became the defining tool for what was then called “the GHS receptor” — the growth hormone secretagogue receptor that wouldn't be identified as the ghrelin receptor (GHS-R1a) until 1999. That history matters for understanding the research literature: decades of GHRP-6 studies were done before researchers fully understood what receptor they were activating and why it produced such a pronounced appetite stimulation signal alongside the GH pulse.

The appetite effect is what separates GHRP-6 from its more selective successors. Ipamorelin also hits GHS-R1a, but with a binding profile engineered to minimize the appetite and gastric motility effects. GHRP-6 doesn't have that selectivity — it activates the receptor broadly enough to drive ghrelin-mediated appetite stimulation alongside the GH signal. In rodent studies, this translates to measurable increases in food intake and body weight gain beyond what the GH elevation alone would predict. That's a confounding variable in muscle growth research (you don't know how much of the mass change comes from GH signaling vs. increased caloric intake), but it also makes GHRP-6 uniquely useful for studying the appetite and gastric biology side of the ghrelin axis — a research question that's distinct from anything ipamorelin can address.

This guide covers how GHRP-6 works at the GHS-R1a receptor, what the published literature shows on GH release, appetite stimulation, and body composition, how it compares with GHRP-2 and ipamorelin, dosing considerations in research protocols, and what to look for when sourcing material.

What is GHRP-6?

GHRP-6 is one of the original synthetic growth hormone-releasing peptides, predating ipamorelin and tesamorelin by about a decade. The hexapeptide acts on the ghrelin receptor and stimulates pituitary GH release with appetite-stimulating, gastric-motility, and modest cardiovascular effects as side activities. The compound is widely used in research for studying ghrelin biology, appetite regulation, and the GH axis in rodent and small clinical settings. It is not approved by Health Canada or the FDA for any therapeutic indication; research-grade GHRP-6 is sold under research-use-only labelling. The peptide is on the World Anti-Doping Agency prohibited list.

How does GHRP-6 work? GHSR-1a and the calcium signal

The receptor target is GHSR-1a. Published research shows that the growth hormone (GH) secretagogue receptor (GHS-R1a) is a G protein-coupled receptor that binds both endogenous ghrelin and synthetic GHRPs including GHRP-6. The receptor is expressed on pituitary somatotrophs, hypothalamic arcuate-nucleus neurons, and several peripheral tissues including the stomach, pancreas, and adrenal cortex.

The intracellular signal cascade is well-characterised. Published research shows that GHRP-6-stimulated GH-secretion involves the diacylglycerol/inositol(1,4,5)trisphosphate pathway with a resulting rise in cytosolic Ca2+ in pituitary somatotrophs. The calcium elevation triggers GH granule exocytosis and the resulting GH release into circulation, which then drives IGF-1 production through the standard hepatic GH-receptor pathway.

Receptor desensitisation is a practical consideration. Published research shows that GHSR-1a is mainly localized at the plasma membrane under unstimulated conditions and rapidly desensitizes after activation, internalising over minutes-to-hours of sustained stimulation. This is why GHRP-6 dosing typically uses 2-3 daily pulses rather than continuous infusion: the receptor recovers between doses and maintains responsiveness.

Does GHRP-6 increase growth hormones?

Yes, in a pulsatile manner. A single GHRP-6 subcutaneous injection raises plasma GH within 15-30 minutes, with peak GH levels 5-10 times baseline at standard research doses. The pulse declines over 60-90 minutes, returning to baseline by 2 hours. IGF-1 elevation follows over 12-24 hours through hepatic GH-receptor signalling. With repeated dosing across days and weeks, sustained baseline GH and IGF-1 levels rise modestly above pre-treatment values.

The magnitude is comparable to ipamorelin but with the additional appetite-stimulating and cortisol-elevating effects that ipamorelin’s more selective structure avoids.

Does GHRP-6 increase weight or stimulate appetite?

Yes. The same GHSR-1a receptor that mediates GH release also drives appetite stimulation through hypothalamic arcuate-nucleus neurons. Published research shows that ghrelin stimulates appetite and induces a positive energy balance leading to body weight gain in rodent and human models. Synthetic GHRPs including GHRP-6 share this ghrelin-mimicking effect.

For body composition research, this is sometimes a useful feature (in cachexia or post-injury appetite-loss models) and sometimes a confound (when GH-axis effects are the desired endpoint and appetite changes complicate the analysis). For weight-loss research, GHRP-6 is the wrong tool; it works in the opposite direction.

GHRP-6 effects on gastric emptying

The ghrelin pathway also drives gastric motility. Published research shows that Ghrelin and GHRP-6 increase gastric emptying in diabetic mice with gastroparesis, supporting potential applications in diabetic gastroparesis research. The pro-motility effect runs through both vagal and direct gastric smooth-muscle pathways.

GHRP-6 vs GHRP-2 and ipamorelin

All three are GH secretagogues acting on GHSR-1a, but with different side-activity profiles:

• GHRP-6: strong appetite stimulation, modest cortisol elevation, modest prolactin elevation, increased gastric motility
• GHRP-2: stronger GH release than GHRP-6 at equivalent dose, less appetite stimulation, similar cortisol/prolactin effects
• Ipamorelin: minimal appetite, no cortisol, no prolactin elevation, selective GH release only

Selection between the three depends on the research question. For appetite biology, GHRP-6 is the right tool. For pure GH release research without confounds, ipamorelin is preferred. For maximum GH release with tolerable confounds, GHRP-2 sits in the middle.

How long does it take for GHRP-6 to work?

Acute GH-pulse effects are visible within 15-30 minutes of a single dose. IGF-1 elevation appears over 12-24 hours after the first dose. Subjective appetite stimulation appears within 30-60 minutes. Body composition effects from sustained dosing typically require 8-12 weeks of consistent multi-daily administration to become measurable. Sleep quality improvements are often reported within 1-2 weeks.

Dosing and cycle length

Research protocols typically use GHRP-6 at 100-300 μg per dose by subcutaneous injection, two to three times daily. The short half-life (~30 minutes) and rapid receptor desensitisation require multi-daily pulsed dosing rather than continuous infusion. Bedtime dosing aligns with natural night-time GH pulses. Typical cycle length is 8-16 weeks of consistent dosing followed by a washout period, although extended-duration research protocols are also documented.

Stacked with the GHRH analogue CJC-1295, the combination produces additive GH effects (pulse-and-baseline coverage) similar to the canonical CJC-1295 + ipamorelin stack but with the appetite-stimulating activity that distinguishes GHRP-6 from ipamorelin.

Side effects and safety

Reported side effects in research and clinical protocols include:

• Increased appetite and hunger (expected from the ghrelin-mimic mechanism)
• Injection-site irritation
• Mild cortisol and prolactin elevation (less than older non-selective GHRPs, more than ipamorelin)
• Transient water retention
• Mild headache
• Possible carpal tunnel-like symptoms at higher doses (from sustained low-dose GH effects)

The cortisol and prolactin side activities are the main downsides relative to ipamorelin and are why ipamorelin has largely displaced GHRP-6 in modern research stacks. For ghrelin-pathway research where appetite is the endpoint, GHRP-6 remains the most relevant tool.

Legal status

GHRP-6 is not approved by Health Canada or the FDA for any therapeutic indication. It is legal in Canada and the United States as a research chemical sold under research-use-only labelling. The peptide is on the World Anti-Doping Agency prohibited list as a growth hormone secretagogue. It was added to the FDA 503A “do not compound” list in 2023, restricting US compounding-pharmacy preparation.

Sourcing for research

Reproducible GH-axis research depends on the integrity of the input material:

• Batch-specific Certificate of Analysis from an independent third-party laboratory
• HPLC purity confirmation at 98 percent or above, with chromatogram trace
• Mass spectrometry verification of the expected ~873 Da hexapeptide molecular weight
• Endotoxin and sterility testing for in vivo or cell-culture work

Reviv Peptides supplies research-grade GHRP-6 with third-party COA and HPLC purity confirmation. View the Reviv Peptides shop for current availability.

Comparison with the GHRH analogue class

GHRP-6 is a GH secretagogue acting on the ghrelin receptor; sermorelin, tesamorelin, and CJC-1295 are GHRH analogues acting on the GHRH receptor. The two classes engage different receptors and produce additive effects when stacked. The practical differences: GHRP-6 has a short half-life and requires multi-daily pulse dosing while CJC-1295 with DAC supports once-weekly administration. GHRP-6 stimulates appetite while the GHRH analogues do not. GHRP-6 raises cortisol modestly while ipamorelin (the selective GHRP successor) does not. For research stack design, pairing a GHRH analogue with either GHRP-6 or ipamorelin is the standard approach; pairing two compounds on the same receptor (e.g. GHRP-6 plus GHRP-2) produces redundant rather than additive effects.

GHRP-6 questions

What is GHRP-6 good for?

GHRP-6 is most useful in research for studying ghrelin-pathway biology, appetite regulation, gastric motility (gastroparesis), and the GH axis. For pure GH research without appetite confounds, ipamorelin has largely displaced GHRP-6 in modern protocols.

What are the benefits of GHRP-6?

Stimulates pulsatile growth hormone release through GHSR-1a, raises IGF-1, increases appetite (useful in cachexia or appetite-loss models), and supports gastric emptying. Effects on body composition are modest and accumulate over months.

Does GHRP-6 increase growth hormones?

Yes. A single dose raises plasma GH 5-10 times baseline within 15-30 minutes. IGF-1 elevation follows over 12-24 hours. Sustained dosing produces modest baseline elevations of both hormones.

How long does it take for GHRP-6 to work?

Acute GH-pulse effects within 15-30 minutes; IGF-1 elevation within 12-24 hours; subjective appetite stimulation within 30-60 minutes; body composition effects over 8-12 weeks of consistent multi-daily dosing.

What are the potential side effects of GHRP-6?

Increased appetite (expected mechanism), injection-site irritation, mild cortisol and prolactin elevation, transient water retention, occasional carpal-tunnel symptoms at higher doses. The cortisol and prolactin side activities are the main downsides relative to ipamorelin.

Key data point: A 2006 study in Growth Hormone & IGF Research showed GHRP-6 at 1 µg/kg IV produced a peak GH elevation of 21 ng/mL in healthy adults (versus a ~1 ng/mL baseline) — a 20-fold amplitude spike matching or exceeding physiological overnight GH pulses and establishing GHRP-6 as the highest-amplitude GH-releasing peptide in the GHRP class at standard doses.

Summary

GHRP-6 is one of the original synthetic growth hormone-releasing peptides, acting on the ghrelin receptor GHSR-1a to stimulate pulsatile GH release alongside appetite stimulation and gastric motility effects. The mechanism runs through DAG/IP3 calcium signal pathway in pituitary somatotrophs. The compound is most useful in research for ghrelin-pathway biology, appetite regulation, and gastric motility research. For pure GH research without confounds, the more selective ipamorelin has largely displaced GHRP-6 in modern protocols. Not approved by Health Canada or the FDA; on the FDA 503A “do not compound” list and the WADA prohibited list. Research-grade material is legal in Canada and the United States under research-use-only labelling.

All products sold by Reviv Peptides are for research and educational purposes only and are not intended for human consumption. Not for diagnostic, clinical, or therapeutic use of any kind.